Impact of Molnupiravir Treatment on Patient-Reported Coronavirus Disease 2019 (COVID-19) Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial

Guan et al., Clinical Infectious Diseases, doi:10.1093/cid/ciad409, MOVe-OUT, NCT04575597

Jul 2023

Source PDF All Studies Meta AnalysisMeta

Symptom recovery details for the MOVe-OUT trial. Results are shown with the main paper1.

Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity2-11. Multiple analyses have identified variants potentially created by molnupiravir12-16.

Important missing comments or errors? Let us know.

1. Jayk Bernal et al., Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, New England Journal of Medicine, doi:10.1056/NEJMoa2116044.nejm.org, doi.org.

2. Swanstrom et al., Lethal mutagenesis as an antiviral strategy, Science, doi:10.1126/science.abn0048.science.org, doi.org.

3. Hadj Hassine et al., Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, Viruses, doi:10.3390/v14040841.mdpi.com, doi.org.

4. Waters et al., Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environmental and Molecular Mutagenesis, doi:10.1002/em.22471.wiley.com, doi.org.

5. Huntsman, M., An assessment of the reproductive toxicity of the anti-COVID-19 drug molnupiravir using stem cell-based embryo models, Master's Thesis, scholarspace.manoa.hawaii.edu/items/cd11342c-b4dc-44c0-8b44-ce6e3369c40b.hawaii.edu.

6. Zibat et al., N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody, iScience, doi:10.1016/j.isci.2023.107786.sciencedirect.com, doi.org.

7. Shiraki et al., Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans, Heliyon, doi:10.1016/j.heliyon.2024.e35331.sciencedirect.com, doi.org.

8. Gruber et al., Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study, Journal of Medical Virology, doi:10.1002/jmv.29642.wiley.com, doi.org.

9. Marikawa et al., An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations, Reproductive Toxicology, doi:10.1016/j.reprotox.2023.108475.sciencedirect.com, doi.org.

10. Zhou et al., β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells, The Journal of Infectious Diseases, doi:10.1093/infdis/jiab247.oup.com, doi.org.

11. Chamod et al., Molnupiravir Metabolite--N4-hydroxycytidine Causes Cytotoxicity and DNA Damage in Mammalian Cells in vitro: N4-hydroxycytidine Induced Cytotoxicity DNA Damage, Asian Medical Journal and Alternative Medicine, 23:3, asianmedjam.com/index.php/amjam/article/view/1448.asianmedjam.com.

12. Focosi et al., The fitness of molnupiravir-signed SARS-CoV-2 variants: imputation analysis based on prescription counts and GISAID analyses by country, Intervirology, doi:10.1159/000540282.karger.com, doi.org.

13. Sanderson et al., A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, Nature, doi:10.1038/s41586-023-06649-6.nature.com, doi.org.

14. Fountain-Jones et al., Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study, The Lancet Microbe, doi:10.1016/S2666-5247(23)00393-2.sciencedirect.com, doi.org.

15. Kosakovsky Pond et al., Anti-COVID drug accelerates viral evolution, Nature, doi:10.1038/d41586-023-03248-3.nature.com, doi.org.

16. twitter.com, twitter.com/LongDesertTrain/status/1597353291868155906.twitter.com/LongDesertTrain/status/1597353291868155906.

Guan et al., 19 Jul 2023, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 18 authors, study period May 2021 - November 2021, average treatment delay 4.0 days, trial NCT04575597 (history) (MOVe-OUT). Contact: yanfen_guan@merck.com.

This Paper Molnupiravir All

Impact of Molnupiravir Treatment on Patient-Reported Coronavirus Disease 2019 (COVID-19) Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial

Merck Yanfen Guan, Amy Puenpatom, Matthew G Johnson, Ying Zhang, Yujie Zhao, Joseph Surber, Aaron Weinberg, Carlos Brotons, Roman Kozlov, Rudy Lopez, Kathleen Coetzee, Joel Santiaguel, Jiejun Du, Angela Williams-Diaz, Michelle Brown, Amanda Paschke, Carisa De Anda, Josephine M Norquist

Clinical Infectious Diseases, doi:10.1093/cid/ciad409

Background. Molnupiravir is an orally administered antiviral authorized for COVID-19 treatment in adults at high risk of progression to severe disease. Here, we report secondary and post hoc analyses of participants' self-reported symptoms in the MOVe-OUT trial, which evaluated molnupiravir initiated within 5 days of symptom onset in nonhospitalized, unvaccinated adults with mild-to-moderate, laboratory-confirmed COVID-19. Methods. Eligible participants completed a 15-item symptom diary daily from day 1 (randomization) through day 29, rating symptom severity as "none," "mild," "moderate," or "severe"; loss of smell and loss of taste were rated as "yes" or "no." Time to sustained symptom resolution/improvement was defined as the number of days from randomization to the first of 3 consecutive days of reduced severity, without subsequent relapse. Time to symptom progression was defined as the number of days from randomization to the first of 2 consecutive days of worsening severity. The Kaplan-Meier method was used to estimate event rates at various time points. The Cox proportional hazards model was used to estimate the hazard ratio between molnupiravir and placebo. Results. For most targeted COVID-19 symptoms, sustained resolution/improvement was more likely, and progression was less likely, in the molnupiravir versus placebo group through day 29. When evaluating 5 distinctive symptoms of COVID-19, molnupiravir participants had a shorter median time to first resolution (18 vs 20 d) and first alleviation (13 vs 15 d) of symptoms compared with placebo. Conclusions. Molnupiravir treatment in at-risk, unvaccinated patients resulted in improved clinical outcomes for most participant-reported COVID-19 symptoms compared with placebo. Clinical Trials Registration. ClinicalTrials.gov: NCT04575597.

References

Abdelnabi, Foo, Jonghe, Maes, Weynand et al., Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model, J Infect Dis

Adjei, Hong, Molinari, Mortality risk among patients hospitalized primarily for COVID-19 during the omicron and Delta variant pandemic periods -United States, MMWR Morb Mortal Wkly Rep

Amdal, Taylor, Kuliś, Health-related quality of life in patients with COVID-19; international development of a patient-reported outcome measure, J Patient Rep Outcomes

Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients, N Engl J Med

Butler, Hobbs, Gbinigie, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial, Lancet

Caraco, Crofoot, Moncada, Phase 2/3 trial of molnupiravir for treatment of COVID-19 in nonhospitalized adults, NEJM Evidence

Danza, Koo, Haddix, SARS-CoV-2 infection and hospitalization among adults aged ≥18 years, by vaccination status, before and during SARS-CoV-2 B. 1.1. 529 (omicron) variant predominance, MMWR Morb Mortal Wkly Rep

Jassat, Karim, Mudara, Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study, Lancet Glob Health

Johnson, Puenpatom, Moncada, Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial, Ann Intern Med

Kluzek, Dean, Wartolowska, Patient-reported outcome measures (PROMs) as proof of treatment efficacy, BMJ Evid Based Med

Madhi, Kwatra, Myers, Population immunity and COVID-19 severity with omicron variant in South Africa, N Engl J Med

Mercieca-Bebber, King, Calvert, Stockler, Friedlander, The importance of patient-reported outcomes in clinical trials and strategies for future optimization, Patient Relat Outcome Meas

Pourkarim, Pourtaghi-Anvarian, Rezaee, Molnupiravir: a new candidate for COVID-19 treatment, Pharmacol Res Perspect

Romano, Fehnel, Stoddard, Development of a novel patient-reported outcome measure to assess signs and symptoms of COVID-19, J Patient Rep Outcomes

Sheahan, Sims, Zhou, An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice, Sci Transl Med

Takashita, Kinoshita, Yamayoshi, Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2, N Engl J Med

Takashita, Yamayoshi, Simon, Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants, N Engl J Med

Wahl, Gralinski, Johnson, SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801, Nature

Watson, Barnsley, Toor, Hogan, Winskill et al., Global impact of the first year of COVID-19 vaccination: a mathematical modelling study, Lancet Infect Dis

Wong, Shah, Johnston, Carlsten, Ryerson, Patient-reported outcome measures after COVID-19: a prospective cohort study, Eur Respir J

Yoon, Toots, Lee, Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses, Antimicrob Agents Chemother

{ 'indexed': {'date-parts': [[2023, 7, 20]], 'date-time': '2023-07-20T04:39:48Z', 'timestamp': 1689827988436}, 'reference-count': 23, 'publisher': 'Oxford University Press (OUP)', 'license': [ { 'start': { 'date-parts': [[2023, 7, 19]], 'date-time': '2023-07-19T00:00:00Z', 'timestamp': 1689724800000}, 'content-version': 'am', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'funder': [{'name': 'Merck, Sharp & Dohme LLC'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': 'Abstract\n' ' \n' ' Background\n' ' Molnupiravir is an orally administered antiviral authorized for ' 'COVID-19 treatment in adults at high risk of progression to severe disease. Here, we report ' 'secondary and post hoc analyses of participants’ self-reported symptoms in the MOVe-OUT ' 'trial, which evaluated molnupiravir initiated within 5 days of symptom onset in ' 'nonhospitalized, unvaccinated adults with mild-to-moderate, laboratory-confirmed ' 'COVID-19.\n' ' \n' ' \n' ' Methods\n' ' Eligible participants completed a 15-item symptom diary daily from ' 'day 1 (randomization) through day 29, rating symptom severity as “none,” “mild,” “moderate,” ' 'or “severe”; loss of smell and loss of taste were rated as “yes” or “no.” Time to sustained ' 'symptom resolution/improvement was defined as the number of days from randomization to the ' 'first of 3 consecutive days of reduced severity, without subsequent relapse. Time to symptom ' 'progression was defined as the number of days from randomization to the first of 2 ' 'consecutive days of worsening severity. The Kaplan-Meier method was used to estimate event ' 'rates at various time points. The Cox proportional hazards model was used to estimate the ' 'hazard ratio between molnupiravir and placebo.\n' ' \n' ' \n' ' Results\n' ' For most targeted COVID-19 symptoms, sustained ' 'resolution/improvement was more likely, and progression was less likely, in the molnupiravir ' 'versus placebo group through day 29. When evaluating 5 distinctive symptoms of COVID-19, ' 'molnupiravir participants had a shorter median time to first resolution (18 vs 20 d) and ' 'first alleviation (13 vs 15 d) of symptoms compared with placebo.\n' ' \n' ' \n' ' Conclusions\n' ' Molnupiravir treatment in at-risk, unvaccinated patients resulted ' 'in improved clinical outcomes for most participant-reported COVID-19 symptoms compared with ' 'placebo.\n' ' Clinical Trials Registration.\u2003ClinicalTrials.gov: ' 'NCT04575597.\n' ' ', 'DOI': '10.1093/cid/ciad409', 'type': 'journal-article', 'created': {'date-parts': [[2023, 7, 19]], 'date-time': '2023-07-19T13:33:58Z', 'timestamp': 1689773638000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Impact of Molnupiravir Treatment on Patient-Reported Coronavirus Disease 2019 (COVID-19) ' 'Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial', 'prefix': '10.1093', 'author': [ { 'given': 'Yanfen', 'family': 'Guan', 'sequence': 'first', 'affiliation': [{'name': 'Merck & Co, Inc , Rahway, New Jersey , USA'}]}, { 'given': 'Amy', 'family': 'Puenpatom', 'sequence': 'additional', 'affiliation': [{'name': 'Merck & Co, Inc , Rahway, New Jersey , USA'}]}, { 'given': 'Matthew G', 'family': 'Johnson', 'sequence': 'additional', 'affiliation': [{'name': 'Merck & Co, Inc , Rahway, New Jersey , USA'}]}, { 'given': 'Ying', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': [{'name': 'Merck & Co, Inc , Rahway, New Jersey , USA'}]}, { 'given': 'Yujie', 'family': 'Zhao', 'sequence': 'additional', 'affiliation': [{'name': 'Merck & Co, Inc , Rahway, New Jersey , USA'}]}, { 'given': 'Joseph', 'family': 'Surber', 'sequence': 'additional', 'affiliation': [{'name': 'Centricity Research , Columbus, Georgia , USA'}]}, { 'given': 'Aaron', 'family': 'Weinberg', 'sequence': 'additional', 'affiliation': [ { 'name': 'Carbon Health Technologies, Inc , North Hollywood, California , ' 'USA'}]}, { 'given': 'Carlos', 'family': 'Brotons', 'sequence': 'additional', 'affiliation': [ { 'name': 'EAP Sardenya, Biomedical Research Institute Sant Pau , Barcelona ' ', Spain'}]}, { 'given': 'Roman', 'family': 'Kozlov', 'sequence': 'additional', 'affiliation': [{'name': 'Smolensk State Medical University , Smolensk , Russia'}]}, { 'given': 'Rudy', 'family': 'Lopez', 'sequence': 'additional', 'affiliation': [ { 'name': 'Clínica Médica Especialista en Pediatría e Infectología ' 'Pediátrica , Guatemala City , Guatemala'}]}, { 'given': 'Kathleen', 'family': 'Coetzee', 'sequence': 'additional', 'affiliation': [{'name': 'Paarl Research Centre , Paarl , South Africa'}]}, { 'given': 'Joel', 'family': 'Santiaguel', 'sequence': 'additional', 'affiliation': [ { 'name': 'Philippine General Hospital, University of the Philippines ' 'Manila , Manila , Philippines'}]}, { 'given': 'Jiejun', 'family': 'Du', 'sequence': 'additional', 'affiliation': [{'name': 'Merck & Co, Inc , Rahway, New Jersey , USA'}]}, { 'given': 'Angela', 'family': 'Williams-Diaz', 'sequence': 'additional', 'affiliation': [{'name': 'Merck & Co, Inc , Rahway, New Jersey , USA'}]}, { 'given': 'Michelle', 'family': 'Brown', 'sequence': 'additional', 'affiliation': [{'name': 'Merck & Co, Inc , Rahway, New Jersey , USA'}]}, { 'given': 'Amanda', 'family': 'Paschke', 'sequence': 'additional', 'affiliation': [{'name': 'Merck & Co, Inc , Rahway, New Jersey , USA'}]}, { 'given': 'Carisa', 'family': 'De Anda', 'sequence': 'additional', 'affiliation': [{'name': 'Merck & Co, Inc , Rahway, New Jersey , USA'}]}, { 'given': 'Josephine M', 'family': 'Norquist', 'sequence': 'additional', 'affiliation': [{'name': 'Merck & Co, Inc , Rahway, New Jersey , USA'}]}], 'member': '286', 'published-online': {'date-parts': [[2023, 7, 19]]}, 'reference': [ { 'key': '2023071919550719200_ciad409-B1', 'doi-asserted-by': 'crossref', 'first-page': '749', 'DOI': '10.1093/infdis/jiab361', 'article-title': 'Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants ' 'of concern in a hamster infection model', 'volume': '224', 'author': 'Abdelnabi', 'year': '2021', 'journal-title': 'J Infect Dis'}, { 'key': '2023071919550719200_ciad409-B2', 'doi-asserted-by': 'crossref', 'first-page': 'e00909', 'DOI': '10.1002/prp2.909', 'article-title': 'Molnupiravir: a new candidate for COVID-19 treatment', 'volume': '10', 'author': 'Pourkarim', 'year': '2022', 'journal-title': 'Pharmacol Res Perspect'}, { 'key': '2023071919550719200_ciad409-B3', 'doi-asserted-by': 'crossref', 'DOI': '10.1126/scitranslmed.abb5883', 'article-title': 'An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in ' 'human airway epithelial cell cultures and multiple coronaviruses in ' 'mice', 'volume': '12', 'author': 'Sheahan', 'year': '2020', 'journal-title': 'Sci Transl Med'}, { 'key': '2023071919550719200_ciad409-B4', 'doi-asserted-by': 'crossref', 'first-page': '1475', 'DOI': '10.1056/NEJMc2201933', 'article-title': 'Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant ' 'BA.2', 'volume': '386', 'author': 'Takashita', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '2023071919550719200_ciad409-B5', 'doi-asserted-by': 'crossref', 'first-page': '468', 'DOI': '10.1056/NEJMc2207519', 'article-title': 'Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, ' 'BA.4, and BA.5 subvariants', 'volume': '387', 'author': 'Takashita', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '2023071919550719200_ciad409-B6', 'doi-asserted-by': 'crossref', 'first-page': '451', 'DOI': '10.1038/s41586-021-03312-w', 'article-title': 'SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801', 'volume': '591', 'author': 'Wahl', 'year': '2021', 'journal-title': 'Nature'}, { 'key': '2023071919550719200_ciad409-B7', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/AAC.00766-18', 'article-title': 'Orally efficacious broad-spectrum ribonucleoside analog inhibitor of ' 'influenza and respiratory syncytial viruses', 'volume': '62', 'author': 'Yoon', 'year': '2018', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '2023071919550719200_ciad409-B8', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients', 'volume': '386', 'author': 'Jayk Bernal', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': '2023071919550719200_ciad409-B9', 'doi-asserted-by': 'crossref', 'first-page': '353', 'DOI': '10.2147/PROM.S156279', 'article-title': 'The importance of patient-reported outcomes in clinical trials and ' 'strategies for future optimization', 'volume': '9', 'author': 'Mercieca-Bebber', 'year': '2018', 'journal-title': 'Patient Relat Outcome Meas'}, { 'key': '2023071919550719200_ciad409-B10', 'doi-asserted-by': 'crossref', 'first-page': '153', 'DOI': '10.1136/bmjebm-2020-111573', 'article-title': 'Patient-reported outcome measures (PROMs) as proof of treatment ' 'efficacy', 'volume': '27', 'author': 'Kluzek', 'year': '2022', 'journal-title': 'BMJ Evid Based Med'}, { 'key': '2023071919550719200_ciad409-B11', 'doi-asserted-by': 'crossref', 'DOI': '10.1183/13993003.03276-2020', 'article-title': 'Patient-reported outcome measures after COVID-19: a prospective cohort ' 'study', 'volume': '56', 'author': 'Wong', 'year': '2020', 'journal-title': 'Eur Respir J'}, { 'key': '2023071919550719200_ciad409-B12', 'doi-asserted-by': 'crossref', 'first-page': '1182', 'DOI': '10.15585/mmwr.mm7137a4', 'article-title': 'Mortality risk among patients hospitalized primarily for COVID-19 ' 'during the omicron and Delta variant pandemic periods—United States, ' 'April 2020-June 2022', 'volume': '71', 'author': 'Adjei', 'year': '2022', 'journal-title': 'MMWR Morb Mortal Wkly Rep'}, { 'key': '2023071919550719200_ciad409-B13', 'doi-asserted-by': 'crossref', 'first-page': 'e961', 'DOI': '10.1016/S2214-109X(22)00114-0', 'article-title': 'Clinical severity of COVID-19 in patients admitted to hospital during ' 'the omicron wave in South Africa: a retrospective observational study', 'volume': '10', 'author': 'Jassat', 'year': '2022', 'journal-title': 'Lancet Glob Health'}, { 'key': '2023071919550719200_ciad409-B14', 'author': 'US Food and Drug Administration.', 'year': '2020'}, { 'key': '2023071919550719200_ciad409-B15', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/EVIDoa2100043', 'article-title': 'Phase 2/3 trial of molnupiravir for treatment of COVID-19 in ' 'nonhospitalized adults', 'volume': '1', 'author': 'Caraco', 'year': '2022', 'journal-title': 'NEJM Evidence'}, { 'key': '2023071919550719200_ciad409-B16', 'author': 'Centers for Disease Control and Prevention', 'year': '2022'}, { 'key': '2023071919550719200_ciad409-B17', 'doi-asserted-by': 'crossref', 'first-page': '281', 'DOI': '10.1016/S0140-6736(22)02597-1', 'article-title': 'Molnupiravir plus usual care versus usual care alone as early treatment ' 'for adults with COVID-19 at increased risk of adverse outcomes ' '(PANORAMIC): an open-label, platform-adaptive randomised controlled ' 'trial', 'volume': '401', 'author': 'Butler', 'year': '2023', 'journal-title': 'Lancet'}, { 'key': '2023071919550719200_ciad409-B18', 'doi-asserted-by': 'crossref', 'first-page': '1126', 'DOI': '10.7326/M22-0729', 'article-title': 'Effect of molnupiravir on biomarkers, respiratory interventions, and ' 'medical services in COVID-19: a randomized, placebo-controlled trial', 'volume': '175', 'author': 'Johnson', 'year': '2022', 'journal-title': 'Ann Intern Med'}, { 'key': '2023071919550719200_ciad409-B19', 'doi-asserted-by': 'crossref', 'first-page': '1293', 'DOI': '10.1016/S1473-3099(22)00320-6', 'article-title': 'Global impact of the first year of COVID-19 vaccination: a mathematical ' 'modelling study', 'volume': '22', 'author': 'Watson', 'year': '2022', 'journal-title': 'Lancet Infect Dis'}, { 'key': '2023071919550719200_ciad409-B20', 'first-page': '1314', 'article-title': 'Population immunity and COVID-19 severity with omicron variant in South ' 'Africa', 'volume-title': 'N Engl J Med', 'author': 'Madhi', 'year': '2022'}, { 'key': '2023071919550719200_ciad409-B21', 'doi-asserted-by': 'crossref', 'first-page': '177', 'DOI': '10.15585/mmwr.mm7105e1', 'article-title': 'SARS-CoV-2 infection and hospitalization among adults aged ≥18 years, ' 'by vaccination status, before and during SARS-CoV-2 B. 1.1. 529 ' '(omicron) variant predominance—Los Angeles County, California, November ' '7, 2021–January 8, 2022', 'volume': '71', 'author': 'Danza', 'year': '2022', 'journal-title': 'MMWR Morb Mortal Wkly Rep'}, { 'key': '2023071919550719200_ciad409-B22', 'doi-asserted-by': 'crossref', 'first-page': '26', 'DOI': '10.1186/s41687-022-00434-1', 'article-title': 'Health-related quality of life in patients with COVID-19; international ' 'development of a patient-reported outcome measure', 'volume': '6', 'author': 'Amdal', 'year': '2022', 'journal-title': 'J Patient Rep Outcomes'}, { 'key': '2023071919550719200_ciad409-B23', 'doi-asserted-by': 'crossref', 'first-page': '85', 'DOI': '10.1186/s41687-022-00471-w', 'article-title': 'Development of a novel patient-reported outcome measure to assess signs ' 'and symptoms of COVID-19', 'volume': '6', 'author': 'Romano', 'year': '2022', 'journal-title': 'J Patient Rep Outcomes'}], 'container-title': 'Clinical Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad409/50913511/ciad409.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad409/50913511/ciad409.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 7, 19]], 'date-time': '2023-07-19T23:58:24Z', 'timestamp': 1689811104000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad409/7226391'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 7, 19]]}, 'references-count': 23, 'URL': 'http://dx.doi.org/10.1093/cid/ciad409', 'relation': {}, 'ISSN': ['1058-4838', '1537-6591'], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'published': {'date-parts': [[2023, 7, 19]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0